

**AREA PRESCRIBING COMMITTEE – ACTION LIST 16<sup>th</sup> JUNE 2016**

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
14/050	134/14	Add second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel.	LA	To be added to Blueteq by August 2016 meeting	11.08.2016	ONGOING
<b>ACTIONS FOR 2016</b>						
15/42	26/15	<b>Annual Declaration of Interest Form</b> To be developed and completed annually by committee members.	LA	Comments back on proposed declarations for the August APC meeting	11.08.2016	ONGOING
15/34	72/15	<b>Vitamin D guidelines (was NG 14 Melanoma assessment and Management)</b> Vitamin D guidelines circulated to the group	LA BG PB	Comments to be sent to Ruth O'Neil by end of June. Final draft to be produced by July 11 <sup>th</sup> for presentation at the provider Medicine Management Group meetings. Final version to be brought to the August APC meeting.	11.08.2016	ONGOING
15/39	111/15	<b>Sulfasalazine SCG</b> Review for gastro indications.	PB	Updated version now includes Rheumatology and Gastro indications, PB to update document removing "and ensure that test results are recorded in the monitoring booklet".	11.08.2016	ONGOING
15/43	126/15	<b>Azathioprine &amp; Mercaptopurine SCG</b> To be reviewed in light of gastroenterologist comments.	LA	LA to review the SCG taking comments from Mr Dennis Burke and Dr Shadad (both NCUHT) into account	11.08.2016	ONGOING
03/16	03/16	<b>Cumbria and Lancashire Formulary (was Lothian Joint Formulary review)</b>  Working group to be set up to discuss the options for formulary in light of discrepancies between Lothian and NICE.	LA	Groups for the formulary review have now been created with section reviews to be completed by mid-September 2016. Lancashire North have joined the project. Final version to be brought to October APC meeting.	13.10.2016	ONGOING
04/16	08/16	<b>Transfer of care audit</b>	AL	Audit results have just been received, to be brought to the August APC meeting.	11.08.2016	ONGOING

14/16	32/16	Acetyl cholinesterase inhibitors – SCG review	HH	Amendments requested to secondary care responsibilities: include the statement- Discharge letter should state “Prescribe drug in line with SCP” APPROVED with this amendment. Final version to August meeting.	11.08.2016	ONGOING
09/16	18/16 & 33/16	Memantine and AChEI – review of RAG rating	HH	Document to be updated by CPFT taking further comments into consideration, including the need for a schedule for introduction of memantine and stop AChEI and monitoring of response. Final draft to be circulated for comments. Final version to next meeting	11.08.2016	ONGOING
18/16	45/16	Recent LJF Formulary decisions  Botulinum toxin type A 50 unit, 100 unit and 200 unit powder for solution for injection Focal spasticity	AL	AL to check to check that this is not a procedure of limited clinical value	11.08.2016	
19/16	46/16	Recent LJF Formulary decisions  Botulinum toxin type A 50 and 100 LD50 units powder for solution for injection Post stroke spasticity of the upper limb	AL	AL to check to check that this is not a procedure of limited clinical value	11.08.2016	
20/16	45/16	LJF Amendments  April 2016 – Chapter 4 CNS	HH	To bring to August APC meeting	11.08.2016	
21/16	46/16	NICE Technology Appraisals  TA388 Sacubitril valsartan Treating symptomatic chronic heart failure with reduced ejection	BG	Full guidance to be brought to August APC meeting. BG to ask NCUHT clinicians if they wish to develop a SCP.	11.08.2016	

		fraction.				
22/16	47/16	<b>NG46 Controlled Drugs: safe use and management</b>	AL	Cumbria do not have a local opioid conversion table. AL to review existing tables.	11.08.2016	
24/16	55/16	<b>Domperidone SCG</b>	PB	To be taken back to the paediatricians at UHBMT for further evidence to support use that is not in line with MHRA guidance.	11.08.2016	
25/16	56/16	<b>PICO dressings RAG review</b>	LA	Proposed SCP discussed and changes suggested including name changed to "prescription request form". To be circulated to the DN team for comment, version to the August APC meeting.	11.08.2016	
26/16	63/16	<b>Stopping over medication for people with learning difficulties</b>	AL	Further information from the NHSE Call to Action (expected June16) to be brought back to August APC meeting.	11.08.2016	
27/16	64/16	<b>Psoriasis Biologics Agents consultation</b>	AL	To be brought to the August APC meeting.	11.08.2016	
28/16	65/16	<b>Sequential use of Biologics in Ulcerative Colitis</b>	AL	To be brought to the August APC meeting.	11.08.2016	
29/16	66/16	<b>Sequential use of Biologics in Crohn's disease</b>	AL	To be brought to the August APC meeting.	11.08.2016	
30/16	67/16	<b>Zero risk schemes in advance of NICE</b>	PB	To be brought to the August APC meeting.	11.08.2016	
31/16	68/16	<b>Off-label uses of tablets and capsules</b>  The current "Specials Guide – Quick wins" contains many out of date recommendations as licensed alternatives are now available.	LA	Updated version to be brought to October meeting.	13.10.2016	
32/16	69/16	<b>Colecalciferol recommendations</b>	BM	BM to send a list to Ruth O'Neil for inclusion	11.08.2016	

		Highlighted the recent increase in the number of licensed vitamin D products available.		in the Vitamin D guidelines.		
33/6	70/17	<b>Fulvestrant RAG rating</b>  The committee approved BLACK rating in view of the time since publication of NICE TA239.	LA	Current prescribing GPs to be informed and SCG to be removed from NECS MO website.	11.08.2016	
34/16	71/16	<b>Blueteq</b>  The lack of updated forms on Blueteq was highlighted as a risk to clinical engagement with the project.	LA	LA to liaise with Lancashire to ensure updated forms are added to Cumbria system, Benepali® as priority.	11.08.2016	
35/16	73/16	<b>Drug Safety Update</b>  Drug Safety Update (April 2016)	LA	Points 1, 7, 8 & 9 add to Prescription Pad	11.08.2016	
36/16	76/16	<b>Submissions to the APC</b>	PU	Briefing paper to be developed	11.08.2016	

	New action from current meeting
	Action over one meeting old
	Action over two meetings old